Corvidia

company

About

Corvidia Therapeutics focuses on the research and development of transformative therapies for cardio-renal diseases.

Details

Last Funding Type
Series A
Last Funding Money Raised
$26M
Industries
Biotechnology,Genetics,Health Care,Medical,Therapeutics
Founded date
Jan 1, 2014
Number Of Employee
11 - 50
Operating Status
Active
Legal Name
Corvidia Therapeutics, Inc.
Also Known As
Corvidia Therapeutics

Corvidia Therapeutics is a clinical stage company focused on the research, development, and commercialization of transformative therapies for cardio-renal diseases. The Company is currently developing potential treatments for chronic kidney disease with atherosclerotic cardiovascular disease and inflammation, and high triglyceride-induced acute pancreatitis.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$86.82M
Corvidia has raised a total of $86.82M in funding over 2 rounds. Their latest funding was raised on Mar 24, 2020 from a Convertable Note round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Mar 24, 2020 Convertable Note $827.33K 1 Detail
Apr 25, 2018 Series B $60M 9 Venrock Detail
Feb 17, 2016 Series A $26M 2 Apple Tree Partners
Sofinnova Partners
Detail

Investors

Number of Lead Investors
Number of Investors
3
9
Corvidia is funded by 9 investors. Venrock and HBM Healthcare Investments AG are the most recent investors.
Investor Name Lead Investor Funding Round
Venrock Yes Series B
HBM Healthcare Investments AG Convertable Note
Andera Partners Series B
Apple Tree Partners Series B
Cormorant Asset Management Series B
Fresenius Medical Care Series B
MedImmune Series B
Sofinnova Partners Series B
Venrock Healthcare Capital Partners Series B

Employee Profiles

Number of Employee Profiles
4
Corvidia has 4 current employee profiles, including Board member Seth Harrison
Board member
Board member
Board member
Board member